Monopar Therapeutics (MNPR), founded in 2014, is a clinical-stage biopharmaceutical company focused on creating groundbreaking therapies for cancer and other life-threatening diseases. Despite its relatively small size within the biotech industry, Monopar’s distinctive approach with its radiopharmaceutical programs to tackle advanced and aggressive cancers has caught Wall Street’s attention.
Last year, the stock skyrocketed by an astounding 1,089%, far outpacing the broader market gain of 24%. While it’s not uncommon for biotech stocks to surge following a drug approval, such a dramatic gain raises questions about the key milestones Monopar achieved to drive this exceptional performance. Let’s find out what fueled Monopar’s remarkable growth and whether the stock has further room to climb this year.
